Sage Journals: Discover world-class research

Abstract

Background:

The presenting symptoms and rate of progression of multiple sclerosis (MS) are very heterogeneous. The diverse clinical manifestations and the clinical course of the disease may vary with modifiable risk factors.

Objective:

To systematically review modifiable risk factors and exposures associated with MS progression.

Methods:

We searched six databases till March 2015, reference-mined reviews, and consulted with experts (PROSPERO 2015:CRD42015016461). Two reviewers screened and extracted data. We used random meta-analysis models and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) to assess the quality of evidence.

Results:

In total, 59 studies met inclusion criteria. Lower vitamin D levels were associated with higher Expanded Disability Status Scale (EDSS) scores (r = −0.22; confidence interval (CI) = −0.32, −0.12; 11 studies; I² = 66%), smokers had an increased risk of MS progression (hazard ratio (HR) = 1.55; CI = 1.10, 2.19; I² = 72%; seven studies), and there was no association of MS progression with the use of epidural analgesics during childbirth delivery (three studies). There was insufficient evidence to draw conclusions for 11 risk factors due to conflicting results or use of different predictor and outcome measures.

Conclusion:

MS progression was consistently associated with low vitamin D levels, and smoking was associated with a more rapid decline in MS disability. Studies used a variety of methods, predictors, and outcomes making it difficult to draw conclusions. Future studies should focus on prospective assessments.

Keywords

Multiple sclerosis multiple sclerosis progression risk factors prognostic study systematic review

Get full access to this article

View all access options for this article.

References

Compston

Coles

Multiple sclerosis. Lancet 2002; 359: 1221–1231.

Herndon

RM.

Medical hypothesis: Why secondary progressive multiple sclerosis is a relentlessly progressive illness. Arch Neurol 2002; 59: 301–304.

D’Hooghe

Nagels

Bissay

. Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler 2010; 16: 773–785.

Hempel

Estrada

. Modifiable risk factors in the progression of multiple sclerosis: A systematic review of the epidemiology and treatment. Los Angeles: Health Services Research & Development Service, U.S. Department of Veterans Affairs, 2015.

Altman

DG.

Systematic reviews of evaluations of prognostic variables. Br Med J 2001; 323: 224–228.

Kurtzke

JF.

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

Hayden

van der Windt

Cartwright

. Assessing bias in studies of prognostic factors. Ann Intern Med 2013; 158: 280–286.

IntHout

Ioannidis

Borm

GF.

The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 2014; 14: 25.

Begg

Mazumdar

Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101.

10.

Egger

Davey Smith

Schneider

. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629–634.

11.

Duval

Tweedie

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455–463.

12.

Huguet

Hayden

Stinson

. Judging the quality of evidence in reviews of prognostic factor research: Adapting the GRADE framework. Syst Rev 2013; 2: 71.

13.

Soilu-Hanninen

Laaksonen

Laitinen

. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosur Ps 2008; 79: 152–157.

14.

Ascherio

Munger

White

. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014; 71: 306–314.

15.

Sundstrom

Nystrom

Smoking worsens the prognosis in multiple sclerosis. Mult Scler 2008; 14: 1031–1035.

16.

Tepavcevic

Kostic

Stojsavljevic

. Cigarette smoking as a predictor for change in disability in multiple sclerosis patients: A 6-year follow-up study in Belgrade (Serbia). Eur J Neurol 2010; 17: 487.

17.

Mowry

Waubant

McCulloch

. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012; 72: 234–240.

18.

Pittas

Ponsonby

van der Mei

. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol 2009; 256: 577–585.

19.

Swank

Dugan

BB.

Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet 1990; 336: 37–39.

20.

Motl

Dlugonski

Pilutti

. Premorbid physical activity predicts disability progression in relapsing-remitting multiple sclerosis. J Neurol Sci 2012; 323: 123–127.

21.

Stuifbergen

Blozis

Harrison

. A longitudinal study of persons with multiple sclerosis. Arch Phys Med Rehab 2006; 87: 935–943.

22.

Powe

Evans

Wenger

. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013; 369: 1991–2000.

23.

Pozuelo-Moyano

Benito-Leon

Mitchell

. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology 2013; 40: 147–153.

24.

Jagannath

Fedorowicz

Asokan

. Vitamin D for the management of multiple sclerosis. Cochrane Db Syst Rev 2010; 12: CD008422.

25.

Handel

Williamson

Disanto

. Smoking and multiple sclerosis: An updated meta-analysis. PloS ONE 2011; 6: e16149.

26.

Farinotti

Vacchi

Simi

. Dietary interventions for multiple sclerosis. Cochrane Db Syst Rev 2012; 12: CD004192.

27.

Rietberg

Brooks

Uitdehaag

BMJ

. Exercise therapy for multiple sclerosis. Cochrane Db Syst Rev 2005; (1): CD003980.

28.

Feinstein

Dalgas

The benefits of exercise in progressive MS: Some cautious optimism. Mult Scler 2014; 20: 269–270.

29.

Dalgas

Stenager

Exercise and disease progression in multiple sclerosis: Can exercise slow down the progression of multiple sclerosis?

Ther Adv Neurol Disord 2012; 5: 81–95.

30.

Lublin

Reingold

Cohen

. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83: 278–286.

31.

Lublin

FD.

New multiple sclerosis phenotypic classification. Eur Neurol 2014; 72(Suppl. 1): 1–5.

32.

Marrie

Hanwell

General health issues in multiple sclerosis: Comorbidities, secondary conditions, and health behaviors. Continuum 2013; 19: 1046–1057.

33.

Overs

Hughes

Haselkorn

. Modifiable comorbidities and disability in multiple sclerosis. Curr Neurol Neurosci Rep 2012; 12: 610–617.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.59 MB